-

Feinstein Institutes Awarded $2.7M From NIH to Research Shock, Sepsis Therapeutic Targets

original Photo Caption: Ping Wang, MD, professor & chief scientific officer at the Feinstein Institutes. (Credit: Feinstein Institutes)

Photo Caption: Ping Wang, MD, professor & chief scientific officer at the Feinstein Institutes. (Credit: Feinstein Institutes)

MANHASSET, N.Y.--(BUSINESS WIRE)--Uncontrolled bleeding or hemorrhagic shock (HS) is the main cause of death in Americans younger than age 44 and accounts for nearly one-third of all deaths following severe traumatic injury. Researchers at The Feinstein Institutes for Medical Research have been awarded a five-year, $2.7 million grant from the National Institutes of Health (NIH) to better understand HS and how it can lead to increased infection and sepsis. Led by Ping Wang, MD, professor & chief scientific officer at the Feinstein Institutes, new studies will explore the molecular mechanisms and potential therapeutic drug targets for those experiencing HS and its related complications.

Car accidents, military traumas and surgical complications are examples of wounds that can lead to HS. After an injury, HS occurs and the body releases extracellular cold-inducible RNA-binding protein (eCIRP). This damage-associated molecular pattern promotes the excess formation of red blood cells, leading to acute lung injury (ALI) mortality. By interrupting eCIRP, scientists hypothesize they might be able to stop the damaging release of inflammatory proteins known as tumor necrosis factor (TNF) to prevent ALI and death.

“Hemorrhagic shock, sepsis and acute lung injury could be a concern of the past if it is better understood how the body reacts to trauma and bleeding-induced incidences,” said Dr. Wang. “By observing the body’s molecular mechanisms, there’s a potential to discover interventions to improve the chance of survival for patients.”

The team will study in detail the role eCIRP has in HS and investigate the beneficial effects and dosage of an inhibitor to prevent HS, ALI and other complications.

“The NIH is funding Dr. Wang’s laboratory research because complications of trauma and hemorrhage are of importance to the nation’s health,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes. “Their studies may reveal the identity of new drug targets and paths to developing highly needed therapies.”

Dr. Wang is a national leader in shock and sepsis research looking to improve our knowledge of the molecular functions that regulate the body’s immune system and inflammation and how proteins can control it. In 2019, he was awarded Scientific Achievement Award by the Shock Society. He also served as the president of the Shock Society in 2016-2017.

About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Matthew Libassi
631-793-5325
mlibassi@northwell.edu

Industry:

Northwell Health

Release Versions
English

Contacts

Matthew Libassi
631-793-5325
mlibassi@northwell.edu

More News From Northwell Health

Northwell to Launch Long Island’s First Pancreas Transplant Program

MANHASSET, N.Y.--(BUSINESS WIRE)--Northwell Health has received approval to launch Long Island’s first adult pancreas transplant program, according to a letter from the New York State Department of Health (DOH). The Northwell Transplant Institute at North Shore University Hospital (NSUH) recently hosted a site visit with DOH officials, the final hurdle before opening the program to new patients. Northwell’s pancreas program will open access to patients across the greater New York and southern C...

32BJ Health Fund and Northwell Direct Announce Largest Direct Healthcare Contract of its Kind in the Country, Delivering Major Savings and Expanding Access to Care

NEW YORK--(BUSINESS WIRE)--32BJ Health Fund, the union health fund representing 100,000 building service workers in the New York metro area, and Northwell Direct, a direct-to-employer health care network that partners directly with employers and labor unions to provide health benefits solutions to their employees, today announced a historic deal that will significantly expand access to high-quality care for 32BJ members and their families while delivering dramatic savings to patients, unions an...

Feinstein Institutes’ Researchers Develop Promising Therapeutic for Sepsis-Induced Acute Lung Injury

MANHASSET, N.Y.--(BUSINESS WIRE)--Scientists at Northwell Health’s Feinstein Institutes for Medical Research are making strides in controlling the severe inflammation that is the hallmark of sepsis. This severe condition occurs when the body’s immune system reaction to infection causes it to attack its own tissues and organs, often resulting in organ failure or death. Researchers have uncovered a critical mechanism driving acute lung injury (ALI) in sepsis, identifying a novel subset of neutrop...
Back to Newsroom